Although studies have shown that α-SMA+ CAFs can promote tumor progression and this protein is associated with TME immunosuppression, depleting α-SMA+ CAFs in a mouse model did not show promising results as a treatment for pancreatic ductal adenocarcinoma8. Here, ACTA1 is linked to neoplasm.